Novo Nordisk Study Data: Hemophilia Breakthroughs and Pipeline Updates
Will Novo Nordisk's impressive new hemophilia data be enough to offset Eli Lilly's aggressive market share gains in the obesity sector?
AstraZeneca Wainua Trial -8.8% After Phase III Miss
Can AstraZeneca contain the damage after the AstraZeneca Wainua Trial miss erased billions in market value in a single session?
Moderna Flu Vaccine -3.4% After FDA Panel Backs Shot
Can the Moderna Flu Vaccine turn an FDA panel win into a real growth story before Wall Street loses patience?
Moderna Strategy +13%: In Vivo CAR-T Surge Lifts MRNA
Can Moderna Strategy turn a vaccine story into a multi-platform biotech growth engine before the market prices it in?
Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology turnaround?
Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote
Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again?
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story?
Moderna Restructuring +6.3% as FDA Momentum Builds
Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test?
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?
Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative?